Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

United Therapeutics stock price, quote, forecast and news

UTHR
US91307C1027
923818

Price

346.19
Today +/-
+3.37
Today %
+1.08 %
P

United Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the United Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the United Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the United Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze United Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

United Therapeutics Stock Price History

DateUnited Therapeutics Price
9/11/2024346.19 undefined
9/10/2024342.46 undefined
9/9/2024348.71 undefined
9/6/2024345.63 undefined
9/5/2024350.01 undefined
9/4/2024353.37 undefined
9/3/2024352.40 undefined
8/30/2024363.55 undefined
8/29/2024360.22 undefined
8/28/2024359.84 undefined
8/27/2024349.23 undefined
8/26/2024346.67 undefined
8/23/2024348.03 undefined
8/22/2024346.87 undefined
8/21/2024351.61 undefined
8/20/2024346.88 undefined
8/19/2024348.58 undefined
8/16/2024320.99 undefined
8/15/2024323.08 undefined

United Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into United Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by United Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects United Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of United Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into United Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing United Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on United Therapeutics’s growth potential.

United Therapeutics Revenue, EBIT and net profit per share

DateUnited Therapeutics RevenueUnited Therapeutics EBITUnited Therapeutics Net Income
2030e4.39 B undefined2.77 B undefined1.01 B undefined
2029e3.69 B undefined2.51 B undefined1.05 B undefined
2028e3.6 B undefined1.87 B undefined1.23 B undefined
2027e3.48 B undefined1.82 B undefined1.23 B undefined
2026e3.42 B undefined1.62 B undefined1.26 B undefined
2025e3.15 B undefined1.6 B undefined1.24 B undefined
2024e2.9 B undefined1.45 B undefined1.12 B undefined
20232.33 B undefined1.19 B undefined984.8 M undefined
20221.94 B undefined990.9 M undefined727.3 M undefined
20211.69 B undefined688.5 M undefined475.8 M undefined
20201.48 B undefined593.6 M undefined514.8 M undefined
20191.45 B undefined633.7 M undefined-104.5 M undefined
20181.63 B undefined805.4 M undefined589.2 M undefined
20171.73 B undefined1.02 B undefined417.9 M undefined
20161.6 B undefined1.06 B undefined713.7 M undefined
20151.47 B undefined699 M undefined651.6 M undefined
20141.29 B undefined538.8 M undefined340.1 M undefined
20131.12 B undefined292.5 M undefined174.6 M undefined
2012916.1 M undefined421.6 M undefined304.4 M undefined
2011743.2 M undefined474.3 M undefined374.4 M undefined
2010592.9 M undefined171.3 M undefined105.9 M undefined
2009358.9 M undefined25.8 M undefined19.5 M undefined
2008281.5 M undefined-82.1 M undefined-49.3 M undefined
2007210.9 M undefined6.3 M undefined12.4 M undefined
2006159.6 M undefined29 M undefined72.6 M undefined
2005115.9 M undefined42.9 M undefined65 M undefined
200473.6 M undefined13.2 M undefined15.4 M undefined

United Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
000000.010.030.050.070.120.160.210.280.360.590.740.921.121.291.471.61.731.631.451.481.691.942.332.93.153.423.483.63.694.39
-----150.00500.0076.6737.7457.5338.2632.0833.8127.4065.3625.5123.2821.9415.3113.749.087.95-5.68-11.002.4213.6214.9020.2024.508.738.441.763.602.4419.00
-----40.0080.0086.7989.0489.5789.3189.5289.3288.8388.6888.0286.9088.1890.2295.2995.4993.8687.8391.9292.7292.7692.1588.96-------
0000000.020.050.070.10.140.190.250.320.530.650.80.991.161.41.531.621.431.331.381.561.782.070000000
0-0-0.01-0.04-0.08-0.05-0.02-0.010.010.040.030.01-0.080.030.170.470.420.290.540.71.061.020.810.630.590.690.991.191.451.61.621.821.872.512.77
-----4,050.00-920.00-60.00-20.7517.8136.5218.242.86-29.186.9828.8963.8045.9626.1441.7747.7166.4059.3649.4843.7239.9940.8351.1451.0550.1250.8647.5452.4252.0468.0163.14
0-0-0.01-0.03-0.08-0.04-0.02-0.010.020.070.070.01-0.050.020.110.370.30.170.340.650.710.420.59-0.10.510.480.730.981.121.241.261.231.231.051.01
--500.00175.00127.27-50.67-37.84-56.52-250.00333.3310.77-83.33-508.33-138.78452.63256.19-18.72-42.7695.4091.479.52-41.5141.25-117.66-594.23-7.5953.0535.3514.1310.061.78-1.99-0.41-14.82-3.25
3.36.716.626.738.540.641.342.346.750.448.344.945.856.159.559.453.353.254.251.246.844.94443.844.647.348.549.70000000
-----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The United Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the United Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (B)TOTAL CAPITAL (B)
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                     
0.010.020.050.220.060.120.070.080.130.230.290.240.230.630.40.480.690.70.951.050.931.421.491.841.932.842.99
00.10.41.51.59.610.214.314.122.525.728.350.673.788.7116.6126.3162.3192.8214.5297.1175.7151.4157.4198.7220.4278.9
00002.70.10.51.54.93.142.32.700000000000000
000.32.967.28.1811.31213.214.426.435.54637.347.866.981.3100107.910193.486.593.8102111.8
000.52.32.72.32.43.91111.919.516.415.428.224.335.446.449.447.459.5115.575.4133.888.3100.4219.2166.2
0.010.020.050.220.070.140.090.110.170.280.350.30.320.760.560.670.910.971.281.421.451.771.862.172.323.383.55
0000.010.010.010.020.020.020.030.070.220.30.310.370.450.470.480.50.490.550.70.740.730.780.861.05
00000.120.020.060.050.050.040.010.10.150.130.340.310.450.120.0400.50.440.771.151.651.321.94
000000.41.60.40000000000000000000
0008.27.976.465.53.110.49.77.4145.93.419.218.123.531.9139.3130.3130.116.616.580.5
002.79.47.57.57.57.57.57.57.57.58.82.58.110.510.710.310.310.313.731.52828282833.7
000.30.10.21.73.111.336.8113.2147246.3256.1218.4223.6182.3246279.5347375.4337.5319.9379.8408.5370.1442518.1
000.010.030.140.040.090.10.120.20.230.580.730.670.960.961.170.910.910.91.431.632.052.452.852.663.62
0.010.020.060.250.210.180.180.210.290.480.590.871.051.431.521.632.091.882.182.332.883.43.914.625.176.047.17
                                                     
100100200200200200200200200200300300600600600600600700700700700700700700700700700
0.010.030.10.360.370.360.370.380.390.410.550.720.80.930.991.021.061.381.791.811.851.942.052.152.252.392.55
-0-0.02-0.05-0.12-0.16-0.19-0.2-0.18-0.12-0.04-0.02-0.09-0.070.030.250.550.731.071.722.432.853.433.333.844.325.046.03
0000001.72.73.61.511.256.61.70-4.131.56.4-9.3-5.91.513.6-17.9-24.6-18.40.9-2
00000000000000000.30.100-1.9-2.33.710.4-4.6-56.4-10.8
00.020.050.240.20.180.170.20.280.370.540.630.730.961.241.571.822.453.54.244.75.395.365.976.547.388.56
0.41.72.36.97.24.74.36.24.13.1220.318.816.147.310.26.777.58.18.423.19.94.13.84.15.6
0.102.24.53.54.55.57.710.415.317.920.929.850.357.267.979.870.988.396.1162.7143140.3182.9170.8225.8292.4
00000.10.10.1000.92.816.561.4126.3108.197.3318.8299.9339.6228.3273.6110.562.8136.3130.8113.3106.4
000000000000220.323601.3282.5126.55.400000000
000.10.10.10.10.800025000000000000250000400
0.51.74.611.510.99.410.713.914.519.3272.757.7330.3428.7212.6176.7687.8504.3440.8332.5444.7276.6463323.3305.4343.2804.4
00.31.81.81.81.8000250023530.368.9265.62750000250250600800800800300
000000000000000000000000000
0002.63.11.81.11.61.83.17.615.727.139.380.58095.6114.5144130.963.766.67096.5104.8104.677.8
00.31.84.44.93.61.11.61.8253.17.6250.757.4108.2346.135595.6114.5144130.9313.7316.6670896.5904.8904.6377.8
000.010.020.020.010.010.020.020.270.280.310.390.540.560.530.780.620.580.460.760.591.131.221.211.251.18
0.010.020.060.250.220.190.190.210.30.640.820.941.121.51.82.12.63.074.094.715.465.986.497.197.758.629.75
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of United Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand United Therapeutics's financial health and stability.

Assets

United Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that United Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of United Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into United Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0-2-12-33-75-37-23-1015657412-4919105217304174340651713417589-104514475727984
0000022222234111720273132323131354549495153
000000000-18-37-7-34-14181136104185000000000
00111-7-13-31-7-2017-51-74-111-208-216-385-202-117-78124-18059-174-141-97
00274121221112904922223425946523731802717727829538527176
000000000001111455511794120162956
000000000001123224610114219529336234610212092153275332
0-2-9-23-31-38-22-820434948-4099211250323425355382643474778-206755598802978
00-1-200-3-7-5-6-15-38-124-95-18-36-111-31-47-49-43-86-184-83-59-120-138-230
00-11-247-134120-47-12-70-101-21-181-162-209-121-163-29533850348-835-820-335-738-486-811-719
00-10-227-134123-40-7-64-8617-56-67-190-85-51-26338555391-749-636-251-679-366-672-489
0000000000000000000000000000
0001000-20024200038-34-1-1-177-133-82500600-5000-100
062258206-204715-178-81913285-187-171-13-429-351-488-2061914385594104
072259206-202614742021336146-218-169-5-576-446-497436611-164475-11
0000000000102921422339303700-13-2-5-10-18-16
0000000000000000000000000000
04111182-17698-5414-132148-9-29151-89-8124113434191-317-3569015666246
0-2.4-10.6-25.7-31.7-39.6-25.9-15.915.637.133.710.2-164.84.3192.9214.2211.7393.4307.9333600.4387.9594-290.3696.4477.4663.7747.6
0000000000000000000000000000

United Therapeutics stock margins

The United Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of United Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for United Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the United Therapeutics's sales revenue. A higher gross margin percentage indicates that the United Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the United Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the United Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the United Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the United Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the United Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

United Therapeutics Margin History

United Therapeutics Gross marginUnited Therapeutics Profit marginUnited Therapeutics EBIT marginUnited Therapeutics Profit margin
2030e88.94 %63.14 %23.07 %
2029e88.94 %68.01 %28.38 %
2028e88.94 %52.03 %34.1 %
2027e88.94 %52.42 %35.49 %
2026e88.94 %47.54 %36.83 %
2025e88.94 %50.86 %39.26 %
2024e88.94 %50.12 %38.78 %
202388.94 %51.06 %42.31 %
202292.17 %51.17 %37.56 %
202192.73 %40.85 %28.23 %
202092.71 %40.02 %34.71 %
201991.88 %43.74 %-7.21 %
201887.79 %49.48 %36.2 %
201793.87 %59.4 %24.22 %
201695.45 %66.41 %44.64 %
201595.29 %47.69 %44.45 %
201490.23 %41.82 %26.4 %
201388.26 %26.19 %15.63 %
201286.98 %46.02 %33.23 %
201188.04 %63.82 %50.38 %
201088.58 %28.89 %17.86 %
200988.6 %7.19 %5.43 %
200889.31 %-29.17 %-17.51 %
200789.47 %2.99 %5.88 %
200689.35 %18.17 %45.49 %
200589.39 %37.01 %56.08 %
200488.72 %17.93 %20.92 %

United Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The United Therapeutics earnings per share therefore indicates how much revenue United Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue United Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates United Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of United Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating United Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

United Therapeutics Revenue, EBIT and net profit per share

DateUnited Therapeutics Sales per ShareUnited Therapeutics EBIT per shareUnited Therapeutics Earnings per Share
2030e98.67 undefined0 undefined22.77 undefined
2029e82.92 undefined0 undefined23.53 undefined
2028e80.96 undefined0 undefined27.61 undefined
2027e78.13 undefined0 undefined27.73 undefined
2026e76.78 undefined0 undefined28.28 undefined
2025e70.8 undefined0 undefined27.8 undefined
2024e65.12 undefined0 undefined25.25 undefined
202346.83 undefined23.91 undefined19.81 undefined
202239.92 undefined20.43 undefined15 undefined
202135.63 undefined14.56 undefined10.06 undefined
202033.26 undefined13.31 undefined11.54 undefined
201933.08 undefined14.47 undefined-2.39 undefined
201837 undefined18.3 undefined13.39 undefined
201738.43 undefined22.83 undefined9.31 undefined
201634.16 undefined22.69 undefined15.25 undefined
201528.63 undefined13.65 undefined12.73 undefined
201423.77 undefined9.94 undefined6.27 undefined
201321 undefined5.5 undefined3.28 undefined
201217.19 undefined7.91 undefined5.71 undefined
201112.51 undefined7.98 undefined6.3 undefined
20109.96 undefined2.88 undefined1.78 undefined
20096.4 undefined0.46 undefined0.35 undefined
20086.15 undefined-1.79 undefined-1.08 undefined
20074.7 undefined0.14 undefined0.28 undefined
20063.3 undefined0.6 undefined1.5 undefined
20052.3 undefined0.85 undefined1.29 undefined
20041.58 undefined0.28 undefined0.33 undefined

United Therapeutics business model

United Therapeutics Corporation, headquartered in Silver Spring, Maryland, is a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with rare and serious diseases. The company is a pioneer in creating life-saving therapies for a variety of conditions, including pulmonary hypertension, chronic lung failure, and lung cancer. United Therapeutics is one of the most popular companies on Eulerpool.com.

United Therapeutics SWOT Analysis

Strengths

1. Established Presence: United Therapeutics Corp has gained a strong footing in the pharmaceutical industry through its years of operation.

2. Diverse Product Portfolio: The company offers a wide range of medications and therapies, catering to various medical conditions and patient needs.

3. Robust Research and Development: United Therapeutics Corp maintains a strong focus on innovation and continually invests in R&D to develop new treatments.

4. Strong Financial Performance: The company has consistently delivered solid financial results, which provides stability and resources for future growth.

Weaknesses

1. Dependence on a Limited Product Range: Despite having a diverse portfolio, United Therapeutics Corp relies heavily on a few key products for the majority of its revenue.

2. High Production Costs: The manufacturing process of certain medications can be expensive, resulting in lower profit margins for the company.

3. Vulnerability to Regulatory Changes: Strict regulations and evolving compliance requirements in the pharmaceutical industry may pose challenges for United Therapeutics Corp.

4. Limited Global Market Reach: The company's operations are primarily focused in specific regions, potentially hindering growth opportunities in untapped markets.

Opportunities

1. Growing Demand for Innovative Therapies: With the increasing prevalence of various medical conditions, there is a significant market demand for new and improved treatment options.

2. Expansion into International Markets: United Therapeutics Corp can explore new markets globally to extend its reach and tap into potential revenue streams.

3. Strategic Partnerships and Collaborations: Forming alliances with other pharmaceutical companies or research institutions can enhance research capabilities and facilitate product development.

4. Technological Advancements: Incorporating cutting-edge technologies into its product offerings can help United Therapeutics Corp stay competitive and meet evolving patient needs.

Threats

1. Intense Competition: The pharmaceutical industry is highly competitive, with numerous companies vying for market share, which may impact United Therapeutics Corp's growth prospects.

2. Patent Expirations: The expiration of patents for certain medications may lead to increased competition from generic drug manufacturers, potentially reducing the company's market share.

3. Regulatory and Legal Challenges: United Therapeutics Corp must navigate complex regulations, potential legal disputes, and ongoing compliance requirements for its products.

4. Economic Uncertainty: Economic fluctuations and changes in healthcare policies can affect customer purchasing power and reimbursement rates, impacting the company's revenue.

United Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

United Therapeutics historical P/E ratio, EBIT, and P/S ratio.

United Therapeutics shares outstanding

The number of shares was United Therapeutics in 2023 — This indicates how many shares 49.7 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue United Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates United Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of United Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating United Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

United Therapeutics Stock splits

In United Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for United Therapeutics.

United Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20246.53 5.85  (-10.35 %)2024 Q2
3/31/20245.76 6.17  (7.04 %)2024 Q1
12/31/20234.27 4.36  (2.12 %)2023 Q4
9/30/20235.14 5.38  (4.59 %)2023 Q3
6/30/20234.6 5.24  (14.02 %)2023 Q2
3/31/20234.62 4.86  (5.31 %)2023 Q1
12/31/20224.6 2.67  (-41.99 %)2022 Q4
9/30/20223.97 4.91  (23.61 %)2022 Q3
6/30/20224.22 2.41  (-42.84 %)2022 Q2
3/31/20223.41 5.03  (47.41 %)2022 Q1
1
2
3
4
5
...
10

Eulerpool ESG Scorecard© for the United Therapeutics stock

Eulerpool World ESG Rating (EESG©)

76/ 100

🌱 Environment

55

👫 Social

99

🏛️ Governance

72

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees51
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

United Therapeutics list of shareholders

%
Name
Stocks
Change
Date
9.87016 % BlackRock Institutional Trust Company, N.A.4,391,23367,69312/31/2023
8.52778 % Wellington Management Company, LLP3,794,010-327,80312/31/2023
6.42591 % Avoro Capital Advisors LLC2,858,8886,38812/31/2023
4.87798 % Renaissance Technologies LLC2,170,214-80,29412/31/2023
4.51703 % Fidelity Management & Research Company LLC2,009,626-321,89112/31/2023
4.37666 % State Street Global Advisors (US)1,947,17767,90712/31/2023
10.46109 % The Vanguard Group, Inc.4,654,1399,66712/31/2023
1.95576 % Janus Henderson Investors870,119-6,44912/31/2023
1.75267 % Geode Capital Management, L.L.C.779,762-50,48412/31/2023
1.45898 % Rothblatt (Martine A)649,09904/18/2024
1
2
3
4
5
...
10

United Therapeutics Executives and Management Board

Dr. Martine Rothblatt68
United Therapeutics Chairman of the Board, Chief Executive Officer (since 1996)
Compensation 5.32 M
Mr. Michael Benkowitz51
United Therapeutics President, Chief Operating Officer
Compensation 2.83 M
Mr. Paul Mahon59
United Therapeutics Executive Vice President, General Counsel, Corporate Secretary
Compensation 2.31 M
Mr. James Edgemond55
United Therapeutics Chief Financial Officer, Treasurer
Compensation 2.01 M
Mr. Christopher Patusky59
United Therapeutics Lead Independent Vice Chairman of the Board
Compensation 562,981
1
2
3

United Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
MannKind Corporation Stock
MannKind Corporation
SupplierCustomer0,670,72-0,220,160,770,93
Eli Lilly and Company Stock
Eli Lilly and Company
SupplierCustomer0,570,370,650,160,780,89
Catalent, Inc. Stock
Catalent, Inc.
SupplierCustomer0,540,110,820,620,740,90
Smiths Group plc Stock
Smiths Group plc
SupplierCustomer0,520,06----
Medtronic plc Stock
Medtronic plc
SupplierCustomer0,490,500,640,590,900,75
Mochida Pharmaceutical Co., Ltd. Stock
Mochida Pharmaceutical Co., Ltd.
SupplierCustomer0,420,48-0,390,09-0,40-0,52
Veeva Systems Inc. Stock
Veeva Systems Inc.
SupplierCustomer0,230,40-0,120,010,270,77
CVS Health Corporation Stock
CVS Health Corporation
SupplierCustomer-0,210,320,54-0,210,820,73
AmerisourceBergen Corporation Stock
AmerisourceBergen Corporation
SupplierCustomer-0,300,150,590,550,870,93
Supernus Pharmaceuticals, Inc. Stock
Supernus Pharmaceuticals, Inc.
SupplierCustomer-0,360,40-0,54-0,360,690,74
1
2

Most common questions regarding United Therapeutics

What values and corporate philosophy does United Therapeutics represent?

United Therapeutics Corp is committed to delivering innovative solutions in the field of biotechnology. With a strong emphasis on patient care and well-being, the company strives to improve the lives of individuals suffering from severe medical conditions. United Therapeutics Corp's corporate philosophy revolves around cultivating a culture of excellence, fostering a collaborative approach, and maintaining a steadfast dedication to scientific research and development. By consistently pushing boundaries and working towards groundbreaking advancements, United Therapeutics Corp aims to provide hope and transformative therapies for patients worldwide.

In which countries and regions is United Therapeutics primarily present?

United Therapeutics Corp is primarily present in the United States.

What significant milestones has the company United Therapeutics achieved?

Founded in 1996, United Therapeutics Corp has achieved several significant milestones. The company developed Remodulin®, a treatment for pulmonary arterial hypertension (PAH) that received FDA approval in 2002. In the following years, the company successfully launched Tyvaso® and Adcirca®, adding to their portfolio of PAH therapies. Moreover, United Therapeutics Corp pioneered the development of Ex-vivo Lung Perfusion (EVLP) technology, which improves the quality of donor lungs for transplantation. The company's efforts in advancing PAH treatments and lung transplantation techniques have greatly impacted the medical field, making United Therapeutics Corp a global leader in the pharmaceutical industry.

What is the history and background of the company United Therapeutics?

United Therapeutics Corp is a leading biotechnology company specializing in the development of innovative therapies for patients with serious medical conditions. Founded in 1996 by Martine Rothblatt, the company has a rich history of pioneering advancements in the field of pulmonary arterial hypertension (PAH) and other rare diseases. United Therapeutics focuses on the research, development, and commercialization of drugs and devices that address the unmet needs of patients worldwide. With a mission to provide hope and improved quality of life, United Therapeutics Corp has successfully introduced several groundbreaking therapies, establishing itself as a trusted global healthcare provider.

Who are the main competitors of United Therapeutics in the market?

The main competitors of United Therapeutics Corp in the market include companies like Gilead Sciences Inc., Actelion Pharmaceuticals Ltd., and Bayer AG.

In which industries is United Therapeutics primarily active?

United Therapeutics Corp is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of United Therapeutics?

The business model of United Therapeutics Corp revolves around the development and commercialization of innovative therapies for patients with life-threatening conditions. The company focuses on the research, regulatory approval, manufacturing, and marketing of pharmaceutical products, primarily in the field of pulmonary arterial hypertension (PAH). United Therapeutics Corp collaboratively works with physicians, patients, and regulatory agencies to bring life-saving treatments to the market. By employing a patient-centric approach and leveraging advanced scientific technologies, United Therapeutics Corp aims to provide effective therapeutic options for individuals suffering from PAH and other critical diseases.

What is the P/E ratio of United Therapeutics 2024?

The United Therapeutics P/E ratio is 15.32.

What is the P/S ratio of United Therapeutics 2024?

The United Therapeutics P/S ratio is 5.94.

What is the AlleAktien quality score of United Therapeutics?

The AlleAktien quality score for United Therapeutics is 9/10.

What is the revenue of United Therapeutics 2024?

The expected United Therapeutics revenue is 2.9 B USD.

How high is the profit of United Therapeutics 2024?

The expected United Therapeutics profit is 1.12 B USD.

What is the business model of United Therapeutics

United Therapeutics Corp is a leading biotechnology company focused on the development and commercialization of innovative therapies for rare and serious diseases. The company has been pursuing a dual-track strategy since its founding in 1996, which includes both the development of novel drugs and the marketing of already approved products. United Therapeutics' core business focuses on developing drugs for the treatment of lung diseases. The company has specialized particularly in pulmonary hypertension, a rare condition in which high blood pressure in the pulmonary arteries leads to narrowing of the blood vessels and can occur especially in young women. Treatment options for pulmonary hypertension have been limited for a long time, but United Therapeutics has made a breakthrough with its various products. One of United Therapeutics' best-known products is Remodulin, an intravenous medication for the treatment of pulmonary arterial hypertension (PAH) that was already approved in 2002. In addition to Remodulin, the company has also introduced Tyvaso, which is administered as a handheld inhaler and offers patients more flexibility in dosage and application. Another product for the treatment of pulmonary hypertension is Orenitram, an oral medication developed for patients who have difficulty using intravenous medications or inhalers. In addition to developing new drugs, United Therapeutics is also working on further developing and improving existing products. An example of this is the implant for partial lung replacement developed by its subsidiary Lung Biotechnology PBC. The implant contains living cells from a donor lung and is implanted into the body to support the function of the heart-lung system and bridge the time until transplantation. Another focus of United Therapeutics is advancing xenotransplantation, in which organs from animals are to be transplanted into humans. The company has already made significant progress in this field and is closely collaborating with other companies and organizations to further improve this technology. Overall, United Therapeutics' business model is focused on long-term growth and the development of innovative therapies. The company invests heavily in research and development and works closely with customers, partners, and other companies to develop groundbreaking solutions for serious and rare diseases. Through its close collaboration with physicians, research institutes, and patient organizations, the company strives to provide patients worldwide with access to life-saving therapies while also providing its shareholders with solid returns.

What is the United Therapeutics dividend?

United Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does United Therapeutics pay dividends?

The dividend cannot currently be calculated for United Therapeutics or the company does not pay out a dividend.

What is the United Therapeutics ISIN?

The ISIN of United Therapeutics is US91307C1027.

What is the United Therapeutics WKN?

The WKN of United Therapeutics is 923818.

What is the United Therapeutics ticker?

The ticker of United Therapeutics is UTHR.

How much dividend does United Therapeutics pay?

Over the past 12 months, United Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, United Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of United Therapeutics?

The current dividend yield of United Therapeutics is .

When does United Therapeutics pay dividends?

United Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of United Therapeutics?

United Therapeutics paid dividends every year for the past 0 years.

What is the dividend of United Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is United Therapeutics located?

United Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von United Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of United Therapeutics from 9/14/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/14/2024.

When did United Therapeutics pay the last dividend?

The last dividend was paid out on 9/14/2024.

What was the dividend of United Therapeutics in the year 2023?

In the year 2023, United Therapeutics distributed 0 USD as dividends.

In which currency does United Therapeutics pay out the dividend?

The dividends of United Therapeutics are distributed in USD.

All fundamentals about United Therapeutics

Our stock analysis for United Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of United Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.